Replies to post #70000 on Biotech Values

[genisi]

KG and ACUR got a priority review for Acurox, an immediate release oxycodone coformulated with niacin, which is KG's 3rd (in addition to Embeda and Remoxy) pending NDA in the abuse resistance opioids arena.


http://www.reuters.com/article/marketsNews/idINBNG16053120090303?rpc=44